Submitted for Publication: May 22, 2012; final revision received August 31, 2012; accepted September 12, 2012.
Published Online: March 6, 2013. doi:10.1001/jamapsychiatry.2013.900
Author Contributions: Drs Roffman and Goff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: Dr Roffman received research support from Pamlab and the Harvard Medical School Division of Health Sciences and Technology–Massachusetts Institute of Technology Clinical Investigator Training Program, which was supported by an unrestricted educational grant from Merck and Pfizer. Dr Achtyes received research support from Eli Lilly and Company, Novartis, AssureRx, Otsuka, and Janssen. Dr Goff has consulted for Indevus Pharmaceuticals, H. Lundbeck, Schering-Plough, Eli Lilly and Company, Takeda, Biovail, Solvay, Hoffman–La Roche, Cypress, Dainippon Sumitomo, Bristol-Meyers Squibb, Abbott Laboratories, Genentech, Merck, Endo Pharmaceuticals, Otsuka, Pfizer, Novartis, Janssen, and GlaxoSmithKline and has received research support from Pfizer, Novartis, Janssen, GlaxoSmithKline, and Pamlab. Drs Roffman and Goff have applied for a US patent, assigned to Massachusetts General Hospital, concerning prediction of treatment response in schizophrenia based on folate-related genes.
Funding/Support: This work was supported by National Institute of Mental Health grant R01MH070831 (Dr Goff) and the Howard Hughes Medical Institute Early Career Physician-Scientist Award (Dr Roffman). This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award UL1 RR 025758, and financial contributions from Harvard University and its affiliated academic health care centers).
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.
Previous Presentation: This work was presented in part at the American College of Neuropsychopharmacology Annual Meeting; December 6, 2011; Waikoloa, Hawaii.
Online-Only Material: Listen to an author interview about this article and others, at http://bit.ly/L4AZtw.
Additional Contributions: Daniel Tuinstra, BA, and Heather Willett, MA, contributed to data acquisition.